All therapiesEvidence snapshot 2026-09-13
Weight & glucose

ABBV-295

A long-acting amylin analogue that activates both amylin and calcitonin receptors.

GLP-1s & metabolic therapies

At a glance

Selected evidence in this atlas
Studied use & population

Early-phase otherwise healthy adults, mostly male (88.3%), with mean BMI below 30; includes overweight and obesity

Study context
Approval & development

Investigational; phase 1 proof of concept reported

Status & indications
Selected efficacy evidence

9.79% reported weight loss · 0.26% loss with placebo · 12 weeks

GUC17-01 multiple ascending dose study · Phase 1 · sponsor · Weekly cohort 5a; dose not separately disclosed (study tested 2–14 mg) · Assuming continued treatment

Evidence & limitations
Important safety context

Mostly mild GI events; no serious adverse events reported.

Safety context
Next milestone

A next milestone is not summarized for this therapy.

Milestone details

Study results apply to their own population, dose and analysis. They do not establish a ranking between therapies.

Evidence in the atlas

1 result

Each result belongs to its own study population, dose and analysis. Open a result for its chart, comparator, safety findings and limitations.

Weight loss

GUC17-01 multiple ascending dose study

9.79% reported weight loss · 0.26% loss with placebo · 12 weeks

Weekly cohort 5a; dose not separately disclosed (study tested 2–14 mg)

Early-phase otherwise healthy adults, mostly male (88.3%), with mean BMI below 30; includes overweight and obesity

LS mean MMRM. Participants unable to continue dosing were withdrawn with no further efficacy collection. Investigational; phase 1 proof of concept reported

Safety context

Mostly mild GI events; no serious adverse events reported.

Limitations: Small early-phase cohort, unlike a general-obesity phase 2/3 trial; target dose and arm size not disclosed in release.

Explore result Compare study AbbVie ABBV-295 phase 1 multiple ascending dose results · 2026-03-09

Biology & identity

Status in this atlas: Investigational; phase 1 proof of concept reported

Hormone activity

AmylinActivates receptorsCalcitoninActivates receptors

A long-acting amylin analogue that activates both amylin and calcitonin receptors.

What do these hormones do? Amylin · Calcitonin

Investigational; no approved trade name identified as of 2026-09-13. ABBV-295 and GUB014295 are development codes.

AbbVie · Exclusive global licensee, leading development and commercialization.; Gubra · Discovery and original development company; licensor to AbbVie.

Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.

The molecule

A long-acting amylin analogue that activates both amylin and calcitonin receptors.
Structure not yet verified

Structure not verified

A long-acting amylin analogue that activates both amylin and calcitonin receptors.

Shown: Peptide drug

An exact-drug structure was not verified in this review. The named PubChem lookup did not return a compound record; no related hormone or analogue is substituted.

ABBV-295

Development timeline

Next milestone

A next milestone is not summarized for this therapy. This does not mean development has ended.

Development history3 selected milestones

ABBV-295 · compound history across indications

Selected milestones only. Earlier studies may be missing; the first listed date should not be interpreted as the start of development.

  1. Global licence announced

    Gubra and AbbVie announced the licensing agreement for GUB014295, an amylin/calcitonin receptor agonist.

    Source

  2. Global licence completed

    AbbVie's annual report records receipt of the exclusive global development and commercialization licence in April 2025.

    Source

  3. Phase 1 multiple-dose results

    AbbVie reported early weight-loss results from the multiple-ascending-dose study; the population was mostly male and had mean BMI below 30.

    Source

Selected sources checked Sep 13, 2026. This is not an exhaustive history.